|
 As the early stage life science landscape continues to shift and investors are raising new funds, altering their mandates or shifting into or out of the sector completely, it's increasingly challenging to stay on top of what life science investors are looking for. If you read this newsletter you know that LSN's philosophy is to find investors that are a fit for your technology and stage of development. This is much more efficient than reaching out blindly using a 'shotgun approach' to approach any investor that has ever been involved in life sciences. Raising capital is all about efficiencies. Remember, it's a numbers game - an executive fundraiser will do infinitely better when reaching out to investors that you know are a fit for your firm. Vetting and regularly adding new investors to your target list is a necessary part of this process. This is why the LSN Investor Platform added a new feature this week... |
|
By Lucy Parkinson, Senior Research Manager, LSN
 If you're a regular attendee of life science investment conferences, you'll have found that most of these conferences offer 15-minute presentation slots as a means of attracting scientist-entrepreneurs to the event. An exclusive speaking spot in which to tell the whole crowd about the breakthrough technology your company is working on can certainly sound like an attractive offering. But in reality, LSN has found that the 15-minute model offers very poor value to entrepreneurs.
Many presenters arrive at the event anticipating this chance to speak about their technology to a large audience of interested investors; however, entrepreneurs will invariably find that these 15-minute presentations are only attended by other CEOs looking to garner IP and positioning, and vendors hoping to sell their services to the presenters, while the attending investors are busy networking or taking partnering meetings elsewhere...
|
 Institutional Strategic Investors: Point-of-Care Institution Panel The lack of capital available for early stage life science companies has brought many different groups with strategic interests to the table. This panel aims to shed light on the institutional strategic companies that are now funding early stage commercial research in the space, many of whom have a primary goal of lowering the cost of care. Moderated by Monique Yoakim-Turk, Partner at the Technology Development Fund of Boston Children's Hospital, the audience will hear from: - Barbara Gamez Sims, Technology Licensing Manager, Mayo Clinic Ventures
- Manu Nair, Vice President, Technology Licensing Manager, Oklahoma Medical Research Foundation
- Chris Coburn, VP, Innovation, Partners HealthCare
- Kanad Das, Program Manager, Stanford SPARK
|
Life Science Investor Mandates 
